Journal of Neural Transmission

, Volume 114, Issue 2, pp 211–217 | Cite as

Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson’s disease

  • M. Stacy
  • R. Hauser


We previously reported that the use of a specifically designed Wearing-Off Questionnaire (WOQ) identified symptoms of wearing-off more frequently than standard assessments conducted by movement disorder specialists during a routine office visit. In the previous study we used a WOQ of 32 symptoms; however this tool was not designed for daily use. In this paper we describe the retrospective development of a simpler, 19-symptom WOQ more suitable for routine clinical use.

Keywords: Parkinson’s disease, wearing-off, non-motor fluctuations 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agid, Y, Olanow, CW, Mizuno, Y 2002Levodopa: why the controversyLancet360575PubMedCrossRefGoogle Scholar
  2. Ahlskog, JE, Muenter, MD 2001Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literatureMov Disord16448458PubMedCrossRefGoogle Scholar
  3. Chaudhuri, KR, Yates, L, Martinez-Martin, P 2005The non-motor symptom complex of Parkinson’s disease: a comprehensive assessment is essentialCurr Neurol Neurosci Rep5275283PubMedGoogle Scholar
  4. Dodel, RC, Berger, K, Oertel, WH 2001Health-related quality of life and healthcare utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesiasPharmacoeconomics1910131038PubMedCrossRefGoogle Scholar
  5. Goetz, CG, Poewe, W, Rascol, O, Sampaio, C 2005Evidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004Mov Disord20523539PubMedCrossRefGoogle Scholar
  6. Marsden, CD, Parkes, JD 1977Success and problems of long-term levodopa therapy in Parkinson’s diseaseLancet1345349PubMedCrossRefGoogle Scholar
  7. Olanow, CW, Stocchi, F 2004COMT inhibitors in Parkinson’s disease: can they prevent and/or reverse levodopa-induced motor complications?Neurology62S72S81PubMedGoogle Scholar
  8. Parkinson Study Group1996Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients not requiring levodopaAnn Neurol392936CrossRefGoogle Scholar
  9. Parkinson Study Group2000Pramipexole vs. levodopa as initial treatment for Parkinson disease: A randomized controlled trialJAMA28419311938CrossRefGoogle Scholar
  10. Stacy, M, Bowron, A, Guttman, M, Hauser, R, Hughes, K, Larsen, JP,  et al. 2005Identification of motor and nonmotor wearing-off in Parkinson’s disease: Comparison of a patient questionnaire versus a clinician assessmentMov Disord20726733PubMedCrossRefGoogle Scholar
  11. Thomas, K, Samanta, J, Mahant, P, Williamson, K, Stacy, M 2002The Ali Project: A web-based database for Parkinson’s diseaseMov Disord17S141Google Scholar
  12. UPDRS Taskforce2003The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendationsMov Disord18738750CrossRefGoogle Scholar
  13. Welsh, M, McDermott, MP, Holloway, RG, Plumb, S, Pfeiffer, R, Hubble, J 2003Development and testing of the Parkinson’s disease quality of life scaleMov Disord18637645PubMedCrossRefGoogle Scholar
  14. Witjas, T, Kaphan, E, Azulay, JP, Blin, O, Ceccaldi, M, Pouget, J,  et al. 2002Nonmotor fluctuations in Parkinson’s disease: frequent and disablingNeurology59408413PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • M. Stacy
    • 1
  • R. Hauser
    • 2
  1. 1.Duke University Medical CenterDurhamUSA
  2. 2.University of South Florida College of MedicineTampaUSA

Personalised recommendations